Results 11 to 20 of about 231,717 (193)

Diagnosis of Transthyretin Amyloid Cardiomyopathy [PDF]

Cardiology and Therapy, 2020
Transthyretin amyloid cardiomyopathy (ATTR-CM) continues to be an easily overlooked, life-threatening, yet treatable cause of heart failure. Furthermore, its elusive diagnosis leads to late or misdiagnosis.
Adam S. Hafeez, Anthony A. Bavry
doaj   +3 more sources

Utility of Genetic Testing in Patients with Transthyretin Amyloid Cardiomyopathy: A Brief Review

Biomedicines, 2023
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly diagnosed condition. Although wild-type transthyretin amyloidosis (ATTRwt) is the most common ATTR-CM, hereditary transthyretin amyloidosis (ATTRv) may also occur.
Ana-Maria Merino-Merino, Jorge Labrador-Gomez, Ester Sanchez-Corral, Pedro-David Delgado-Lopez, Jose-Angel Perez-Rivera   +4 more
doaj   +2 more sources

Acoramidis in Transthyretin Amyloid Cardiomyopathy

New England Journal of Medicine
To the Editor: In a phase 3 trial of acoramidis for transthyretin amyloid cardiomyopathy, Gillmore et al. (Jan. 11 issue)(1) used the Finkelstein-Schoenfeld test to assess the hierarchical composite primary outcome. They expressed the treatment effect as a win ratio, thereby following the initial presentation of the analysis of a prioritized outcome.(2)
VERBEECK, Johan, De Backer, Mickael, BUYSE, Marc   +2 more
openaire   +6 more sources

Case Report: A rare transthyretin mutation p.D58Y in a Chinese case of transthyretin amyloid cardiomyopathy [PDF]

Frontiers in Cardiovascular Medicine
Hereditary transthyretin amyloid (ATTRv) cardiomyopathy (CM) is caused by mutations in the TTR gene. TTR mutations contribute to TTR tetramer destabilization and dissociation, leading to excessive deposition of insoluble amyloid fibrils in the myocardium
Jibin Lin, Jibin Lin, Jibin Lin, Jiangtong Peng, Jiangtong Peng, Jiangtong Peng, Bingjie Lv, Bingjie Lv, Bingjie Lv, Zheng Cao, Zhijian Chen, Zhijian Chen, Zhijian Chen   +12 more
doaj   +2 more sources

Hereditary transthyretin amyloid cardiomyopathy

Singapore Medical Journal, 2023
10.4103/singaporemedj.SMJ-2021-300 ; Singapore medical journal ; 64 ; 1 ; 74 ...
Yiliang Zheng, Ching-Hui Sia, Raymond Ching Chew Wong, Roger Sik Yin Foo, Weiqin Lin, Devinder Singh, Yoke Ching Lim   +6 more
doaj   +3 more sources

False‐positive bone scintigraphy denoting transthyretin amyloid in elderly hypertrophic cardiomyopathy [PDF]

ESC Heart Failure, 2021
A positive nuclear scintigraphy with hydroxy bisphosphonate bone tracer (99mTc‐HPD) is believed to have high sensitivity (>99%) and specificity (91%) for the diagnosis of transthyretin amyloid cardiomyopathy. We report the case of an 85‐year‐old man with
Cristina Chimenti, Maria Alfarano, Viviana Maestrini, Nicola Galea, Giuseppe De Vincentis, Romina Verardo, Francesco Fedele, Andrea Frustaci   +7 more
doaj   +2 more sources

Reply: Bio-Profiling of Transthyretin Amyloid Cardiomyopathy.

JACC. Heart failure, 2021
Reply: Bio-Profiling of Transthyretin Amyloid ...
Rapezzi C., Sultan M. B., Maurer M. S.
openaire   +4 more sources

Speckle Tracking and Transthyretin Amyloid Cardiomyopathy

Arquivos Brasileiros de Cardiologia, 2016
Background: Amyloidosis is a disease caused by deposits of insoluble fibrils in extracellular spaces. The most common type of familial amyloidosis is mediated by mutation of transthyretin, especially Val30Met.
Alexandre Marins Rocha, Suzane Garcia Ferreira, Marcelo Souto Nacif, Mario Luiz Ribeiro, Marcos Raimundo Gomes de Freitas, Cláudio Tinoco Mesquita   +5 more
doaj   +5 more sources

Transthyretin Amyloid Cardiomyopathy Treatment: An Updated Review

Journal of Clinical Medicine
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive form of restrictive cardiomyopathy caused by the misfolding and deposition of transthyretin protein. What was once a condition that had little by way of treatment other than liver transplantation has now become a manageable disease due to revolutionary novel therapies. This review outlines
Dinusha Wanniarachchige, Shazli Khan, Stephen Pan   +2 more
openaire   +4 more sources

Healthcare resource use of patients with transthyretin amyloid cardiomyopathy

ESC Heart Failure, 2022
Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is the cardiac manifestation of transthyretin amyloidosis (ATTR). The aim of this study was to estimate healthcare resource use for ATTR‐CM patients compared with heart failure (HF) patients, in Denmark,
Rosa Lauppe, Johan Liseth Hansen, Anna Fornwall, Katarina Johansson, Mark H. Rozenbaum, Anne Mette Strand, Merja Vakevainen, Johanna Kuusisto, Einar Gude, J. Gustav Smith, Finn Gustafsson   +10 more
doaj   +2 more sources